Conditional Metastasis of Uveal Melanoma in 8091 Patients over Half-Century (51 Years) by Age Group: Assessing the Entire Population and the Extremes of Age.
Journal
Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701
Informations de publication
Date de publication:
03 Jul 2023
03 Jul 2023
Historique:
medline:
10
7
2023
pubmed:
7
7
2023
entrez:
7
7
2023
Statut:
ppublish
Résumé
To evaluate cumulative incidence of metastasis at specific timepoints after treatment of uveal melanoma in a large cohort of patients and to provide comparison of conditional outcomes in the youngest and oldest cohorts (extremes of age). Retrospective analysis of 8091 consecutive patients with uveal melanoma at a single center over a 51-year period. The patients were categorized by age at presentation (0-29 years [n = 348, 4%], 30-59 years [n = 3859, 48%], 60-79 years [n = 3425, 42%], 80 to 99 years [n = 459, 6%]) and evaluated for nonconditional (from presentation date) and conditional (from specific timepoints after presentation) cumulative incidence of metastasis at five, 10, 20, and 30 years. For the entire population of 8091 patients, five-year/10-year/20-year/30-year nonconditional cumulative incidence of metastasis was 15%/23%/32%/36%, and the conditional incidence improved to 6%/15%/25%/30% for patients who did not develop metastasis in the first three years. For the extremes of age (0-29 years and 80-99 years), the nonconditional cumulative incidence of metastasis revealed the younger cohort with superior outcomes at 8%/15%/19%/27% and 21%/29%/29%/29%, respectively (P < 0.001). The conditional incidence (at one-year and two-year timepoints with metastasis-free survival) showed persistent superior younger cohort survival (P < 0.001, P = 0.001), but no further benefit for patients with three-year metastasis-free survival at 4%/12%/16%/24% and 7%/18%/18%/18%, respectively (P = 0.09). Non-conditional metastasis-free survival analysis for patients with uveal melanoma revealed the youngest cohort to have significantly better survival than the oldest cohort, and this persisted into one-year and two-year conditional metastasis-free survival but diminished at the three-year conditional timepoint.
Identifiants
pubmed: 37418273
pii: 2791284
doi: 10.1167/iovs.64.10.7
pmc: PMC10337788
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7Références
Indian J Ophthalmol. 2021 Jul;69(7):1839-1845
pubmed: 34146040
Ophthalmology. 2016 Apr;123(4):898-907
pubmed: 26854035
Ophthalmol Retina. 2021 Jun;5(6):536-542
pubmed: 32979556
Dis Colon Rectum. 2016 Apr;59(4):291-8
pubmed: 26953987
Ophthalmic Genet. 2022 Dec;43(6):742-755
pubmed: 36369870
Arch Ophthalmol. 2009 Aug;127(8):989-98
pubmed: 19667335
Indian J Ophthalmol. 2019 Dec;67(12):1959-1963
pubmed: 31755428
Ophthalmology. 2018 Aug;125(8):1139-1142
pubmed: 30032793
JAMA Ophthalmol. 2016 Jul 1;134(7):734-40
pubmed: 27123792
JAMA Oncol. 2018 Aug 1;4(8):1129-1130
pubmed: 30003235
Nat Rev Dis Primers. 2020 Apr 9;6(1):24
pubmed: 32273508
Ophthalmology. 2019 Oct;126(10):1445-1453
pubmed: 31026493
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Saudi J Ophthalmol. 2021 Nov 17;36(3):308-314
pubmed: 36276251
Ann Surg Oncol. 2010 Jun;17(6):1662-8
pubmed: 20165985
Cancer. 2013 Oct 15;119(20):3589-92
pubmed: 23913639
Cancer Cell. 2017 Aug 14;32(2):204-220.e15
pubmed: 28810145
Oman J Ophthalmol. 2013 May;6(2):116-8
pubmed: 24082672
Am J Ophthalmol. 2018 Nov;195:154-160
pubmed: 30092184
Ophthalmology. 2022 Apr;129(4):431-437
pubmed: 34793831
Saudi J Ophthalmol. 2022 Jun 13;35(4):279-285
pubmed: 35814983
Curr Opin Ophthalmol. 2019 May;30(3):206-214
pubmed: 30844944
Melanoma Res. 2016 Feb;26(1):77-82
pubmed: 26479218
Acta Ophthalmol. 2023 Feb;101(1):34-48
pubmed: 35801361
Ophthalmology. 2015 Jun;122(6):1180-6
pubmed: 25813452
Cancer. 2010 May 1;116(9):2234-41
pubmed: 20187100
Ophthalmology. 2015 Feb;122(2):414-28
pubmed: 25439609
Eur J Cancer. 2014 Feb;50(3):602-10
pubmed: 24262585
Invest Ophthalmol Vis Sci. 2020 Mar 9;61(3):31
pubmed: 32186672
JAMA Oncol. 2018 Aug 1;4(8):1130-1131
pubmed: 30003231
JAMA Ophthalmol. 2020 Mar 1;138(3):260-267
pubmed: 31944225
Contemp Oncol (Pozn). 2015;19(1A):A68-77
pubmed: 25691825
Ophthalmology. 2013 Oct;120(10):2066-71
pubmed: 23664467
Retina. 2012 Jul;32(7):1363-72
pubmed: 22466491
Cancers (Basel). 2016 Feb 02;8(2):
pubmed: 26848688